Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leuk...

por Niswander, Lisa M., Graff, Zachary T., Chien, Christopher D., Chukinas, John A., Meadows, Christina A., Leach, Lillie C., Loftus, Joseph P., Kohler, M. Eric, Tasian, Sarah K., Fry, Terry J.
Publicado 2022

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

por Qin, Haiying, Yang, Lila, Chukinas, John A, Shah, Nirali N, Tarun, Samiksha, Pouzolles, Marie, Chien, Christopher D, Niswander, Lisa M, Welch, Anthony R, Taylor, Naomi A, Tasian, Sarah K, Fry, Terry J
Publicado 2021

CD38 as a pan-hematologic target for chimeric antigen receptor T cells

por Glisovic-Aplenc, Tina, Diorio, Caroline, Chukinas, John A., Veliz, Kimberly, Shestova, Olga, Shen, Feng, Nunez-Cruz, Selene, Vincent, Tiffaney L., Miao, Fei, Milone, Michael C., June, Carl H., Teachey, David T., Tasian, Sarah K., Aplenc, Richard, Gill, Saar
Publicado 2023

Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML

por Popescu, Bogdan, Stahlhut, Carlos, Tarver, Theodore C., Wishner, Sydney, Lee, Bianca J., Peretz, Cheryl A.C., Luck, Cuyler, Phojanakong, Paul, Camara Serrano, Juan Antonio, Hongo, Henry, Rivera, Jose M., Xirenayi, Simayijiang, Chukinas, John A., Steri, Veronica, Tasian, Sarah K., Stieglitz, Elliot, Smith, Catherine C.
Publicado 2023